Pharmaceutical Technology

APRIL 19, 2023

Camlipixant is being assessed in the CALM Phase III clinical development programme, with anticipated regulatory approval and launch in 2026. Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential.

Specialization 97

Specialization Medicine Sales Patients 97

European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 96

Marketing Sales Physicians Patients 96

European Pharmaceutical Review

APRIL 18, 2023

Camlipixant, a novel P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,” Miels added. According to GSK, the P2X3 antagonist has the potential to deliver significant sales through 2031 and beyond. Camlipixant is anticipated to gain regulatory approval and be launched in 2026.

Biopharma 85

Biopharma Sales Patients Medical 85

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 90

Biopharma Sales Prescription FDA 90

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

APRIL 10, 2023

Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. With reported sales of $32.7m (Rs2.68bn), Galvus is anticipated to boost Cipla’s portfolio in the diabetes care segment.

Manufacturing 52

Manufacturing Medicine Pharma Sales 52

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Competition Marketing Physicians 111

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 10, 2023

billion by 2026, according to research by the Business Research Company. Silicon Valley-based Treasure Data has developed a range of tools that liberate previously siloed data to be unified and utilised so that pharma engagements can be tailored to specific HCP needs that in turn deliver sales and boost brand reputation.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

pharmaphorum

AUGUST 5, 2022

Innovent is responsible for developing the drug in China, picking up exclusive marketing rights there, with Sanofi in line for up to €80 million in milestone payments as well as royalties on sales if it gets approved.

Side effects 83

Side effects Marketing Pharma Medicine 83

pharmaphorum

OCTOBER 17, 2022

It remains to be seen whether the data from VALOR will convince the regulator to grant conditional approval while it waits for results from a confirmatory phase 3 trial (ATLAS ) in SOD1-ALS, which is due to generate results in 2026.

FDA 52

FDA Prospecting Competition Safety 52

pharmaphorum

JANUARY 18, 2023

AI-based medical imaging was a market worth more than $400 million in 2021, according to figures cited by Bayer, and is expected to have a compound annual growth rate (CAGR) of more than 26% between 2020 to 2026, driving its value to around $1.36 The business generated sales of €1.8 billion (approximately $1.9

Medical 57

Medical Pharma Media Sales 57

European Pharmaceutical Review

FEBRUARY 14, 2023

billion in 2026 at a CAGR of 8.5 The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the HPAPI market, the research found. The post HPAPI global market to reach $34.04b in 2026 appeared first on European Pharmaceutical Review.

Marketing 109

Marketing Safety Pharmaceutical Manufacturing 109

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Given the volume of 340B sales (13% of total U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Spotio

JUNE 6, 2022

More empowered buyers has resulted in longer sales cycles. And, 50-90% of the journey is complete before a buyer interacts with a sales rep. This shift in behavior should be taken seriously by any sales team, whether inside or out in the field. Here is a list of 130 sales statistics broken out across 20 categories.

Sales 111

Sales Prospecting B2B Sales CRM 111

Pharmaceutical Technology

JULY 26, 2022

This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.

Marketing 122

Marketing Transportation Leads Patients 122

Legacy MEDSearch

JULY 7, 2023

Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs. from Kerecis (incl. billion (around DKK 8.9 billion), consisting of USD 1.2 billion (around DKK 8.2

Recruitment 52

Recruitment Management Medical Networking 52

pharmaphorum

NOVEMBER 25, 2022

In early 2026, Grünenthal intends to buy out the remaining stake in the JV to claim full control of the products, which include fentanyl-based products Abstral and PecFent for breakthrough cancer pain, Moventig (naloxegol) for opioid-induced constipation, and nutritional supplement Adcal-D3 for osteoporosis.

Medicine 52

Medicine Marketing Pharma Management 52

pharmaphorum

SEPTEMBER 23, 2022

Its reaction to the OCEAN data has been confusing, with an initial decision to withdraw the drug from sale as a result of the negative OS finding later overturned with little explanation for the change of heart.

FDA 52

FDA Patients Marketing Pharma 52

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 10, 2023

billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Mounjaro is forecast to compete for significant market share with semaglutide and also Lilly’s Trulicity (dulaglutide), reaching peak sales of $10.2

Marketing 52

Marketing Physicians Leads Competition 52

Spotio

APRIL 21, 2023

Recent research shows that the hardware as a service market (HaaS) should reach $300+ billion in 2026. If your reps don’t actually use said research to contact and convert leads, your company won’t make sales. You can then adjust your department’s sales strategy to suit. More sales in less time.

Sales 52

Sales Prospecting Leads Sales pitches 52

PM360

SEPTEMBER 21, 2023

United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020. It’s clear that specialty-focused therapies will continue to grow, and GoodRx can be a valuable partner to pharma manufacturers in this space. Qualtrics Brand Tracker Survey of GoodRx users, June 2021 – July 2022.

Prescription 52

Prescription Medical Distribution Patients 52

pharmaphorum

JULY 5, 2022

Indeed, she emphasised that the work done on ensuring access to novel CAR-T therapies was the ‘poster child’ for how it should be done – engaging early with industry partners and collecting informative real-world evidence to guide decision-making.

Patients 92

Patients Medicine Marketing Recruitment 92

World of DTC Marketing

MAY 9, 2022

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. Buying programmatic ads can be an excellent way to quickly grow your company’s contacts list and create new sales opportunities. Not a single brand noticed this, and not a single media buyer noticed the fraud.

Pharma 208

Pharma Media Marketing Sales 208

European Pharmaceutical Review

NOVEMBER 24, 2022

With predictions that the global market for anticounterfeiting packaging is set to reach almost $250 billion by 2026, growth in authentication and anti-tamper devices such as holograms appear to have a healthy future.” Elsewhere, holographic labels have been deployed effectively to arrest declining sales of pharmaceuticals.

Pharmaceutical 101

Pharmaceutical Manufacturing Pharmaceutical products Distribution 101

Evolve Your Success

JANUARY 24, 2023

In this episode, Samuel Adeyinka interviews Caitlin Baker , who shares her journey of transitioning from nursing to aesthetics device sales representative. It’s because she’s a graduate of our Medical Sales Career Builder program. Caitlin was a nurse that wanted to get into medical sales. Her story is unique.

Medical sales 52

Medical sales Sales Medical Education 52

PM360

SEPTEMBER 28, 2022

Maximum Fair Prices published: The first round of negotiated Maximum Fair Prices will be published in August 2024, scheduled to take effect in 2026. Plan bids will reflect negotiated prices for the first time in 2025 (for the 2026 plan year), affecting formulary and coverage strategies. Considerations for Medicare Part B drugs.

Government 97

Government Manufacturing Prescription Competition 97

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Furthermore, the 2020 post-pandemic launches, for which we now have up to 21 months of sales, show continued average underperformance.

Doctors 57

Doctors Medicine Marketing Prescription 57

pharmaphorum

NOVEMBER 6, 2022

Synagis is a former blockbuster – first approved back in 1998 – and is still making solid sales despite losing patent protection, with AZ booking $410 million from the drug last year. However, revenues from the antibody are expected to drop sharply once Beyfortus and vaccines for RSV prevention enter the market.

Marketing 62

Marketing Sales Manufacturing Pharma 62

Pharmaceutical Technology

JANUARY 16, 2023

The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. Some companies may also modify their R&D strategies to keep costs down.

Pharma 64

Pharma Manufacturing Pharmaceutical Marketing 64

Pharmaceutical Technology

JANUARY 16, 2023

The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. Some companies may also modify their R&D strategies to keep costs down.

Pharma 52

Pharma Manufacturing Pharmaceutical Marketing 52